- Home
- SLGL vs RDI Comparison
SLGL vs RDI Comparison
Compare SLGL & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- RDI
- Stock Information
- Founded
- SLGL 1997
- RDI 1937
- Country
- SLGL Israel
- RDI United States
- Employees
- SLGL N/A
- RDI N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- RDI Movies/Entertainment
- Sector
- SLGL Health Care
- RDI Consumer Discretionary
- Exchange
- SLGL Nasdaq
- RDI Nasdaq
- Market Cap
- SLGL 30.9M
- RDI 32.3M
- IPO Year
- SLGL 2018
- RDI N/A
- Fundamental
- Price
- SLGL $0.90
- RDI $1.43
- Analyst Decision
- SLGL Strong Buy
- RDI Hold
- Analyst Count
- SLGL 2
- RDI 1
- Target Price
- SLGL $5.00
- RDI $2.40
- AVG Volume (30 Days)
- SLGL 1.4M
- RDI 157.9K
- Earning Date
- SLGL 03-12-2025
- RDI 11-14-2024
- Dividend Yield
- SLGL N/A
- RDI N/A
- EPS Growth
- SLGL N/A
- RDI N/A
- EPS
- SLGL N/A
- RDI N/A
- Revenue
- SLGL $11,707,000.00
- RDI $197,270,000.00
- Revenue This Year
- SLGL $772.97
- RDI N/A
- Revenue Next Year
- SLGL N/A
- RDI $14.40
- P/E Ratio
- SLGL N/A
- RDI N/A
- Revenue Growth
- SLGL 869.93
- RDI N/A
- 52 Week Low
- SLGL $0.33
- RDI $1.22
- 52 Week High
- SLGL $1.65
- RDI $2.07
- Technical
- Relative Strength Index (RSI)
- SLGL 48.02
- RDI 51.96
- Support Level
- SLGL $0.83
- RDI $1.38
- Resistance Level
- SLGL $1.40
- RDI $1.50
- Average True Range (ATR)
- SLGL 0.21
- RDI 0.09
- MACD
- SLGL -0.04
- RDI 0.01
- Stochastic Oscillator
- SLGL 10.70
- RDI 71.43
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.